Back to Search
Start Over
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients
- Source :
- Annals of Oncology, 23(12), 3091-3097. Elsevier Ltd., Annals of Oncology, 23(12), 3091-3097
- Publication Year :
- 2012
- Publisher :
- Elsevier BV, 2012.
-
Abstract
- Background: Many adverse events (AEs) associated with aromatase inhibitors (AIs) involve symptoms related to the depletion of circulating estrogens, and may be related to efficacy. We assessed the relationship between specific AEs [hot flashes (HF) and musculoskeletal AEs (MSAE)] and survival outcomes in Dutch and Belgian patients treated with exemestane (EXE) in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Additionally, the relationship between hormone receptor expression and AEs was assessed. Methods: Efficacy end points were relapse-free survival (RFS), overall survival (OS) and breast cancer-specific mortality (BCSM), starting at 6 months after starting EXE treatment. AEs reported in the first 6 months of treatment were included. Specific AEs comprised HF and/or MSAE. Landmark analyses and Cox proportional hazards models assessed survival differences up to 5 years. Results: A total of 1485 EXE patients were included. Patients with HF had a better RFS than patients without HF [multivariate hazard ratio (HR) 0.393, 95% confidence interval (CI) 0.19–0.813; P= 0.012]. The occurrence of MSAE versus no MSAE did not relate to better RFS (multivariate HR 0.677, 95% CI 0.392–1.169; P = 0.162). Trends were maintained for OS and BCSM. Quantitative hormone receptor expression was not associated with specific AEs. Conclusions: Some AEs associated with estrogen depletion are related to better outcomes and may be valuable
- Subjects :
- Adult
Oncology
medicine.medical_specialty
Antineoplastic Agents
Breast Neoplasms
Disease-Free Survival
aromatase inhibitors
chemistry.chemical_compound
breast cancer
Breast cancer
SDG 3 - Good Health and Well-being
Exemestane
Internal medicine
medicine
Humans
Adverse effect
Aged
Aged, 80 and over
Gynecology
Proportional hazards model
business.industry
Surrogate endpoint
Hazard ratio
estrogen receptors
Hematology
Middle Aged
medicine.disease
adverse events
Confidence interval
Androstadienes
Postmenopause
Treatment Outcome
chemistry
Chemotherapy, Adjuvant
Female
Neoplasm Recurrence, Local
business
exemestane
Tamoxifen
medicine.drug
Subjects
Details
- ISSN :
- 09237534
- Volume :
- 23
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi.dedup.....4f35efb307553a73021f5c6836b20327